awmsg logo



cangrelor (Kengrexal®)


Reference No. 675

Publication date:
16/07/2015


Appraisal information

cangrelor (Kengrexal®) 50 mg powder for concentrate and diluent for solution for infusion


Company: The Medicines Company
BNF category: Cardiovascular system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 15/07/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, cangrelor (Kengrexal®) cannot be endorsed for use within NHS Wales co-administered with acetylsalicyclic acid (ASA) for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.
Statement of Advice (SOA)
Download